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The problem
Helicobacter pylori infects the gastric mucosa of half the human population, leading to chronic
gastric inflammation in all and clinically important adverse outcomes in a sizable minority. While
most infections with this gram-negative bacterium are not associated with symptoms, gastric or
duodenal ulcers ultimately develop in approximately 10% of colonized individuals, with gastric
adenocarcinoma or mucosal-associated lymphoid tissue lymphoma occurring in about 1%,
decades after the initial infection. H. pylori infection is unevenly distributed, being most prevalent
in resource-poor countries (in the range of 70-90%) and in as few as 10% or less of some
Western populations [1]. Excitement about developing a vaccine based on the genome of H.
pylori abated soon after the sequence was published, when effective antibiotic therapy was
discovered. Unfortunately, the multidrug regimens that are required to eradicate infection
currently remain out of reach for most of the affected patients, they do not prevent re-infection,
and antibiotic-resistant strains are increasingly common [2].

The recent emergence of resistance to antimicrobial therapy has stirred new interest in the
development of an anti-H. pylori vaccine [3], but the complex immunopathogenesis of H. pylori
has frustrated successful vaccine development. H. pylori elicits an intense inflammatory
response to infection, involving the recruitment of multiple innate and adaptive immune cell
populations to the stomach. However, persistent infection for the lifetime of the host usually
follows, demonstrating that this bacterium successfully evades natural host defenses. Most
evidence points to an initial pro-inflammatory response mounted by type 1 T helper CD4+ cells
(Th1) producing interferon-γ that is eventually dampened by CD4+CD25high regulatory T cells
(Treg) expressing FoxP3 [4]. As a result, the pathogen is not eradicated, and persistent infection
develops, contributing to the development of chronic gastritis. A successful vaccine, be it
prophylactic or therapeutic, must be able to tip the immune system balance in favor of an
immune Th1 response that will overcome the immunosuppressive properties of Tregs naturally
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induced by H. pylori. Neither whole inactivated H. pylori, bacterial vectored vaccines expressing
H. pylori proteins, nor recombinant subunit vaccines have demonstrated protective immunity in
clinical trials despite their recognition by humoral and cell-mediated arms of the immune system.
The time is ripe for a novel approach to vaccine design that overcomes the limitations of these
conventional approaches.

A promising solution
Advances in the fields of genomics and computation have led to the emergence of a new
approach to vaccine development, better known as reverse vaccinology or genome-to-vaccine
design. The field is only about 10 years old, yet the first reverse vaccinology product, Novartis’
Bexsero, a vaccine against meningococcus B, is about to be licensed in Europe. One of the
major hurdles facing reverse vaccinologists is choosing the best candidate immunogens from
the wealth of targets provided by whole-genome sequencing. The number of antigens
comprised by bacterial pathogens can be quite large. The genetic diversity of hypermutating
viruses with much smaller genomes can also pose a significant problem. Moreover, the genomic
landscape is amplified by diversity within a single species [5].

Bioinformatics tools developed to harness the emerging genomic sequence “haystack” can be
used to identify potentially immunogenic proteins by their predicted subcellular localization (e.g.
membrane proteins or secreted proteins) or homology to virulence factors of related pathogens.
Together with proteomics data describing antigen expression abundance and kinetics, these
tools narrow down ‘antigen-space’ considerably but they themselves do not provide
immunological direction to vaccine antigen selection. Perhaps the most utilitarian tool, in this
regard, is the T-cell epitope predictor. A T-cell epitope peptide derived from an invading
pathogen interfaces with a major histocompatibility complex (MHC) molecule at an antigen
presentation cell surface and a T cell receptor at the T cell surface. This interaction is essential
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for activation of protective adaptive immune responses. CD8+ and CD4+ T cells play important
roles in containing infections and protection after re-exposure. CD4+ T cell responses are critical
for robust CD8+ T cell proliferation and function and for their differentiation into memory cells
[6,7]. Moreover, CD4+ T cell responses help B cells to produce antibodies that are the mediators
of protection in all currently approved human vaccines [8]. Thus, a T-cell epitope predictor may
identify pathogen-derived sequences that are good vaccine antigens and/or identify key T cell
epitopes that are important adjuncts for effective humoral immune response. Furthermore, as
cognate T cell help improves the quality and kinetics of antibody responses, T-cell epitope
predictors, when used to identify proteins that have the greatest number of T cell epitopes, may
be particularly useful for fishing out good candidates for whole antigen vaccines.

We have developed a genome-to-vaccine strategy, with a central role for T-cell epitope
predictors, that identifies immunogenic and protective T-cell epitopes. While it can be
specifically tailored to a microbe’s particular immunopathogenic profile, this approach can be
generally applied to any pathogen, according to the following steps: 1) Genomes are
computationally mined to identify genes that encode proteins with promising antigenic properties
such as secretion, up-regulated expression, reported immunogenicity and virulence [9,10].
Alternatively, with no experimental bias introduced, complete open reading frame datasets can
be analyzed. 2) Immunoinformatics tools are then used to discover sequences likely to bind to
MHC proteins for presentation to T cells. To cover a large swath of MHC polymorphisms,
‘supertype’ alleles are screened. For personalized vaccine design, the particular MHC type of an
individual would be considered. Depending on the correlate of protective immunity that is
desired, proteins can be triaged by epitope content (those with more T cell epitopes may be
better immunogens), or epitopes can be selected and used as the vaccine “payload.” 3) Where
epitopes are being used to vaccinate, the next step is to synthesize selected sequences as
peptides and evaluate for MHC binding and antigenicity in infection survivors or vaccinees. 4)
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Finally, prototype vaccines are designed, constructed and evaluated for immunogenicity and
efficacy in humanized mice [11]. If epitope-driven vaccines are the objective, the resulting
epitopes may be formulated as multiple peptides, as concatamers in the form of DNA or
delivered as multi-epitope protein vaccines. Clearly, this strategy strips a pathogen down to the
minimal essential sequence information needed to generate immunity, thereby removing the
pathogen’s inherent adjuvant and delivery properties that make it naturally immunogenic.
Building these features back into the final product is necessary, of course, but a key advantage
of epitope-based vaccine design is that it allows for the subsequent selection of best-in-class
adjuvant and delivery technologies.

We have applied this genomes-to-vaccine approach to develop an H. pylori therapeutic vaccine
that was evaluated in the p27 knockout mouse model of gastric cancer induced by chronic H.
pylori infection [12,13]. The H. pylori J99 and 26695 genomes were screened for CD4+ T-cell
epitopes that bind both human and mouse MHC, using the predictor algorithm EpiMatrix. To
identify epitopes with potential to recognize multiple MHC types for broad coverage of the MHCdiverse human population, we used the ClustiMer algorithm, which finds regions of a protein
with high epitope density. Epitope cluster predictions were experimentally validated for MHC
binding and T cell reactivity in p27 knockout mice infected with the mouse-adapted H. pylori
strain SS1. Immunoreactive epitopes that bound MHC and that were also present in strain SS1
were assembled into a multi-epitope vaccine in DNA and peptide formats using a heterologous
prime-boost immunization strategy. The multi-epitope vaccine administered intranasally to SS1infected mice induced a broad immune response as determined by interferon-γ production in
ELISpot assays; much broader, in fact (when examining immune responses to the epitopes),
than the response elicited by a whole bacterial lysate which would have included the proteins
from which the epitopes were derived. This result was paralleled in H. pylori burden in mice
immunized intranasally, which exhibited a significant reduction compared with mice vaccinated
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with whole bacterial lysate. Histopathological indices of inflammation and gastric cellular
damage were low at the distal timepoint that was evaluated, and not significantly different
among the experimental groups.

Emerging issues in epitope selection
We have long considered T-cell epitopes that are conserved between self and infectious
pathogens to potentially drive cross-reactive T cells toward immune disequilibrium under the
inflammatory conditions of vaccination. These sequences have therefore been excluded from
our vaccines. Our current thinking about T-cell epitope selection is evolving as new data
demonstrate that the human microbiome actively shapes immune responses. Post-thymic
educated regulatory T cells play a critical role in orchestrating this interaction via antigen
presentation [14], and thus we believe careful consideration must be given to T-cell epitope
sequences conserved between commensals and infectious pathogens, much in the same way
that we do for self. As the gut microbiome is estimated to contain approximately 33 million
genes, the amount of sequence data to sort through to identify the molecular specificities of
these T cells is staggering. We are now beginning to design a new class of computational tools
and data analysis methods to handle this enormous task.

Conclusion
The utility of the genome-to-vaccine approach for developing vaccines for pathogens has been
emerging from our work and others [15,16,17,18]. The convergence of genomics, bioinformatics
and immunology has expanded our vaccine design toolkit and the results generated thus far
suggest that there is new hope for tackling the many pathogens against which we currently lack
effective vaccines. Proof-of-concept studies for a T-cell epitope-driven H. pylori vaccine
demonstrate this potential, and we expect that fine-tuning the epitope selection criteria will help
epitope-based vaccines take their place amongst conventional vaccines that have already had
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so great an impact on human health.
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